Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

October 6, 2022 updated by: University Health Network, Toronto

A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition

The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes in the pelvis. It might also help doctors tell whether or not cancer has spread to these lymph nodes. It might allow radiotherapy to be delivered more accurately.

Study Overview

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • histologically confirmed endometrial, cervix, prostate (cT1-cT3) or bladder cancer
  • no distant metastases
  • informed consent

Exclusion Criteria:

  • confirmed prostate carcinoma and PSA less than or equal to 4 or greater than 100
  • radical surgery or prior cryosurgery for prostate carcinoma, previous RT, hormonal manipulation or chemotherapy
  • biopsy-proven lymph node involvement
  • endometrium or cervix carcinoma who have undergone recent pelvic surgery with the exclusion of D&C or biopsy
  • bladder carcinoma with recent pelvic surgery with the exclusion of TURBT
  • previous or concurrent cancers other than superficial basal or squamous cell skin carcinoma unless disease-free for at least 5 yrs
  • contraindication to MR imaging
  • hip prosthesis
  • major medical or psychiatric illness
  • patients with known allergy to dextran or iron-containing compounds
  • patients with cirrhosis or hemochromatosis
  • patients receiving another MR contrast within 2 hrs prior to the ferumoxtran-10

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Improved delineation of normal pelvic lymph nodes in patients with uterine, cervical, bladder and prostate cancers.
Time Frame: once at time of imaging
once at time of imaging
Improved clinical target volume (CTV) definition for the purpose of adjuvant irradiation of pelvic lymph nodes using intensity modulated radiotherapy (IMRT).
Time Frame: once at time of imaging
once at time of imaging

Secondary Outcome Measures

Outcome Measure
Time Frame
Comparison of target lymph node delineation between nodal imaging with USPIO and volume expansion of vascular anatomy.
Time Frame: once at time of imaging
once at time of imaging
Demonstration of the pattern and distribution of pelvic nodal metastases in patients with uterine, cervical, bladder and prostate cancers.
Time Frame: once at time of imaging
once at time of imaging

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael Milosevic, MD, Princess Margaret Hospital, Canada

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2004

Primary Completion (Actual)

June 1, 2006

Study Completion (Actual)

March 15, 2022

Study Registration Dates

First Submitted

September 12, 2005

First Submitted That Met QC Criteria

September 12, 2005

First Posted (Estimate)

September 16, 2005

Study Record Updates

Last Update Posted (Actual)

October 7, 2022

Last Update Submitted That Met QC Criteria

October 6, 2022

Last Verified

October 1, 2022

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe